Skip to content

Patch testing in cutaneous Adverse Drug Reactions

CLINICO-DERMOSCOPIC AND PATCH TEST PROFILE IN PATIENTS WITH CUTANEOUS ADVERSE DRUG REACTIONS ATTENDING A TERTIARY CARE FACILITY.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/06/053765
Enrollment
300
Registered
2023-06-12
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L989- Disorder of the skin and subcutaneous tissue, unspecified

Interventions

None listed

Sponsors

GOVERMENT MEDICAL COLLEGE SRINAGAR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients suspected of having cutaneous adverse drug reactions involving delayed hypersensitivity mechanism based on history, time course and clinical pattern. 2) Patients aged above 12 years irrespective of gender. 3) Patients belonging to ethnic Kashmiri population. 4) Those giving willful consent to dermatological examination.

Exclusion criteria

Exclusion criteria: EXCLUSION CRITERIA 1) Patients with active drug eruption. 2) Those having CADRs involving immediate hypersensitivity reaction/ mechanism, based on history, time course and clinical pattern such as urticaria, angioedema and anaphylaxis 3) Non-immunological or pseudo-anaphlactoid reactions 4) Use of topical corticosteroids over patch test site and or away from test site within two weeks of patch test 5) Those receiving systemic treatment such as corticosteroids, immuno- suppressants and phototherapy. 6) Those on antihistamines in preceding two weeks. 7) Rash due to viral infections and non-drug allergens. 8) Patients with known allergy to patch test materials i.e. adhesive tape (micropore), patch test chambers. 9) Those below 12 years of age. 10) Pregnant and lactating females.

Design outcomes

Primary

MeasureTime frame
To determine the patch test sensitivity in patients with cutaneous adverse drug reactions using commercially available standardized antigens (10% in petrolatum or water). Compare the rate of positivity obtained by using standardized patch test antigen (10%) with that of patch test antigens prepared from the suspected commercial drug diluted to 10% and 30% in petrolatum or water.Timepoint: 2yrs

Secondary

MeasureTime frame
â?¢ To study the clinic-demographic profile and dermoscopic findings in patients with cutaneous adverse drug reaction attending a tertiary care hospital. â?¢ To evaluate the role of dermoscopy in the interpretation of patch tests and describe the main findings of the reaction. Timepoint: 2yrs

Countries

India

Contacts

Public ContactShagufta parveen rather

Government medical college Srinagar

shagufta.giri@gmail.com7889501893

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026